Venous Thromboembolism Risk in Lupus Nephritis Not Limited to Class 5
This the first study to evaluate the risk for venous thromboembolism by lupus nephritis class, according to investigators.
This the first study to evaluate the risk for venous thromboembolism by lupus nephritis class, according to investigators.
Trial findings suggest a calcimimetic may be more effective than a VDRA at reducing calcification in patients receiving hemodialysis.
In a short-term trial involving hemodialysis patients, ziltivekimab significantly improved erythropoietin resistance index.
A current meta-analysis of HIF-PHIs showed that these drugs improve the response rate of hemoglobin and decrease hepcidin levels.
In a Japanese study, approximately 1 in 8 CKD patients with anemia failed to respond to darbepoetin alfa therapy.
Despite favorable efficacy data, the HIF-PHI failed to demonstrate noninferiority to the ESA in patients with CKD with respect to the primary MACE safety endpoint.
Transferrin saturation and ferritin concentrations improved significantly more in the ferric citrate than ferrous sulfate group over 12 weeks.
Low hemoglobin levels in patients with IgAN increase their risk for end-stage kidney disease, according to new research.
In a phase 3 trial, mean hemoglobin was maintained within target range during 52 weeks of treatment with oral daprodustat.
Investigators found sex and racial differences in the risk for end-stage kidney disease among patients with CKD anemia.